Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions (NYSE:EBS) announced that senior management will participate in several upcoming investor conferences in late May and early June 2026.
Events include Goldman Sachs leveraged finance and global healthcare conferences, the Benchmark Healthcare House Call Virtual Investor Conference, and the Jefferies Global Healthcare Conference with webcast presentations and options for one-on-one meetings.
Emergent BioSolutions (NYSE:EBS) announced Saudi Food and Drug Authority approval of ACAM2000 [Smallpox and Mpox (Vaccinia) Vaccine, Live] for preventing smallpox and mpox in individuals at high risk of infection.
ACAM2000 is the first Emergent product licensed by SFDA and includes boxed warnings for serious potential complications.
Emergent BioSolutions (NYSE: EBS) reported Q1 2026 revenue of $156.1 million, net income of $6.8 million (4% margin) and adjusted EBITDA of $35.6 million (23% margin).
The company completed a $150 million term loan refinancing, secured strategic manufacturing partnerships including Substipharm, authorized up to $50 million of share repurchases, and won material government contracts including ~$140 million with Canada.
Emergent BioSolutions (NYSE:EBS) said Singapore’s Health Sciences Authority approved an expanded indication for ACAM2000 to include prevention of mpox in adults at high risk for mpox infection.
The approval is supported by existing human safety data and a controlled animal study showing vaccine effectiveness, and permits use during severe mpox outbreaks when alternatives are unavailable or contraindicated.
Emergent BioSolutions (NYSE: EBS) signed a multi-year manufacturing agreement with SAB Biotherapeutics to support development and manufacturing of SAB-142, a type 1 diabetes clinical candidate. The contract value is approximately $50 million, with $36 million contingent on regulatory approval and downstream milestones. Emergent will provide end-to-end process development, scale-up, analytical transfer, clinical manufacturing and potential commercial manufacture at its Winnipeg, Manitoba facility, which will act as the primary site for bulk intermediate and drug product production for SAB-142.
Emergent BioSolutions (NYSE: EBS) partnered with professional baseball player Davis Schneider to raise awareness of NARCAN® Nasal Spray in Canada and to reduce stigma around opioid poisonings. Schneider shares his family story on Emergent’s Opioid Crisis Impact Map to encourage preparedness and naloxone access.
The release notes an average of 17 lives lost daily to opioid poisoning in Canada and > 53,000 lives lost since 2016. Since 2018, Emergent has delivered more than 100 million doses of NARCAN® Nasal Spray across Canada and the U.S., and lists provincial, territorial and other program access points and an online ordering option.
Emergent BioSolutions (NYSE: EBS) and Substipharm Biologics agreed to a ≈$34.5 million manufacturing services and distribution collaboration dated April 28, 2026. Emergent’s Canton, MA facility will manufacture IMOJEV® drug substance and serve as exclusive U.S. government distributor upon FDA approval.
The Canton site received an FDA "No Action Indicated" classification after a February 2026 inspection; Emergent has begun scale-up work and expects to hire additional staff later in 2026.
Emergent BioSolutions (NYSE: EBS) will report first quarter 2026 financial results and host a conference call on April 30, 2026 at 5:00 p.m. ET.
Investors can join via live webcast on the company Investors page or register for telephone access; a replay will be posted on the Investors page.
Emergent BioSolutions (NYSE: EBS) closed a new $150 million term loan with OrbiMed and amended its asset-backed revolving loan to $50 million, extending maturities for both facilities to April 16, 2031. Interest on the new term loan was reduced by 200 basis points, and covenant flexibility and incremental debt capacity were expanded to support the company’s multi-year transformation plan.
The proceeds repaid the prior term loan, and the ABL amendment increases operational flexibility and borrowing options to pursue strategic initiatives.
Emergent BioSolutions (NYSE: EBS) announced a supply partnership with the B.C. Provincial Health Services Authority to provide NARCAN® Nasal Spray as British Columbia expands its Take-Home Naloxone Program following an $18 million CAD provincial investment.
The rollout expands a 2024 pilot that delivered 60,000 nasal kits; Emergent reports delivering >100 million NARCAN doses in Canada and the U.S. since 2016 and employs over 300 people in Canada.